Associate Director Community Outreach- 🫁Thoracic Oncology, University of Miami @SylvesterCancer , 🇵🇷Boricua, Co-founder @KidsHelpingKidsSucceed
Miami, FL
Joined June 2012
- Tweets14.7K
- Following3K
- Followers8.5K
- Likes19.2K
📣 Join us for LungÕ 2026 Virtual Global Congress on Lung Oncology coming up Nov 5th
👉🏽a great end of the year virtual review of thoracic oncology
👉🏽 with an international list of expert speakers focusing on early detection, precision diagnostics, multidisciplinary treatment and global onc.
Honored to cochair this congress with @glopesmd #lcsm
#lungcancer
oncodaily.com/lungo-2026-vir…
Dr. Estela Rodriguez retweeted
My essay @ThePublicSquare
A New American Casts His First Vote zocalopublicsquare.org/a-new…
I Grew Up in the Shadow of Dictatorship. Now I’m Putting My Trust in This Republic
@SclcSMASHERS @FDA @LUNGevity @lungoncdoc @StephenVLiu @HHorinouchi @g_mountzios @sands_jacob @LauraAlderMD @oncodaily @OncoAlert @Latinamd @LuisPaz_Ares @RManochakian @LuisRaezMD @triparnasen @LaurenByersMD @LungCancerEu @alissajcooper @BZhangMD @NaglaAKarimMD @Annechiangmd @IASLC @NCCN @ASCO #ESMO26 @larvol @tribeMDUS @sylvestercancer @oncbrothers @chinmay @Jani_Chinmay @colazagasti @openmedicineHQ @myesmo @openmedkate @openmedben @chadinabhan @YoungLungCancer @OncodailyLung @ClinicalLung #LCSM @LungPolicy @dan_morgxen @LAGurwitch
🚨Great news for patients with #EGFRex20ins #lungcancer #Sunvozertinib finally available for dispensation in the US following FDA approval in July 2025.
📌 Approved for previously treated patients based on WU-KONG1B:
🔹 ORR: 46% (95% CI 35–57)
🔹 DoR: 11.1 mo (95% CI 8.2–NE)
📊 In the WU-KONG28 Phase III trial, first-line sunvozertinib vs carbo/pem (n=324) showed:
🔹 ORR: 59% vs 31%
🔹 DoR: 11.2 vs 7.1 mo
🔹 PFS: 10.3 vs 7.5 mo (HR 0.65)
🔹 12-mo PFS: 46% vs 27%
💊 200mg po daily
⚠️ Monitor for ILD/pneumonitis, GI and skin toxicity, ocular toxicity
⚠️ Diarrhea: 75% G3+: 5%) @EGFRResisters
🇧🇷 Obrigada, @IASLC! Excited to travel to São Paulo for #LALCA Nov 12-14 and share perspectives on incorporating ADCs and bispecific antibodies into lung cancer management.
🎙️Scientific Session ES10.03
📅 Nov 13 | 11:45 AM
Looking forward to connecting with colleagues across Latin America! 🇧🇷 #LungCancer
Dr. Estela Rodriguez retweeted
Lung cancer screening can detect cancer before symptoms appear, yet many eligible Americans aren't getting screened.
Following Pope Leo’s lung cancer diagnosis, Sylvester’s Dr. Coral Olazagasti (@COlazagasti) spoke with @PreventionMag about barriers to screening, the importance of early detection and why individual risk factors matter. spr.ly/6013BHXrKD
As a Catholic and thoracic oncologist, I’m delighted by the encouraging news about @Pontifex’s recovery and surgical results ! 🙏 His doctors report no need for additional treatment based on pathology and molecular testing—a wonderful outcome of early stage lung cancer 🫁 and prayers answered.
Equally remarkable: final results in just 8 days after surgery, while many patients wait weeks for molecular testing in the advanced setting. This is a reminder that timely results and biomarker testing matter! 💜
Pope Leo XIV’s doctors have confirmed that the tumor removed on October 13 was a lung adenocarcinoma and that the disease was localized.
Dr. Luigi Carbone and Professor Stefano Margaritora said on Wednesday evening that a subsequent oncological assessment has confirmed that “no further treatment is necessary.”
Dr. Estela Rodriguez retweeted
Check out my latest article: The Other Decoupling
In 2009, “decoupling” meant hoping Asia could grow despite an American downturn. Today, it means deliberately weakening US–China connections.
Returning to Singapore in 2026, I reread a letter I wrote during the financial crisis—and saw what years of investment in healthcare had built.
“The Other Decoupling” reflects on a lesson for families and countries alike: protection against uncertainty has to be built before it is needed.
linkedin.com/pulse/other-dec… via @LinkedIn
I see @dan_morgen @HemOncMiami fellow in this picture. I know Dr Edith Mitchell @eaonc would have loved to meet him and all these talented trainees- her legacy of creating opportunity and supporting a diverse physician scientist workforce lives on! #Representationmatters
Congratulations to the Fall 2026 Edith Peterson Mitchell, MD Health Equity Travel Scholars: Kamryn Clay, @belladreyfuss25, Dr. Ekpenyong, Dr. Gabra, Alaina Hawkins, @xlabissieremd, @dan_morgen, @PhyuNaing4, @OgaKingsley, & Kennedy Stacy #CancerResearch #ClinicalTrials #eaonc
Dr. Estela Rodriguez retweeted
🫁🧬 Sincere thanks to @eaonc for inviting me back as a former Edith Peterson Mitchell Award recipient to share our ongoing research at @SylvesterCancer.
My talk focused on two important aspects of lung cancer research:
🌍 Understanding the evolving epidemiology and global burden of lung cancer risk factors.
🧬 Exploring how genomic alterations and the tumor immune landscape differ across age groups.
Grateful for the opportunity to share our work and connect with fellow investigators! @GlopesMd @Latinamd @dan_morgen @HemOncMiami @DesaiP_Oncdoc @BenBleibergMD
Dr. Estela Rodriguez retweeted
How do you balance toxicity risks with the potential for improved outcomes?
Watch as experts @Latinamd, Matthew Gumbleton, MD, PhD, of @huntsmancancer, and Siddhartha Devarakonda, MD, of @ProvSwedish, discuss the conversations they have with patients when weighing treatment-related adverse effects against survival benefits in EGFR-mutated NSCLC.
Watch now: hubs.li/Q04z20T40
#NSCLC #LungCancer #Oncology
Dr. Estela Rodriguez retweeted
We reported a 42.9% five-year relative survival rate for malignant brain and nervous system cancers, compared with 32.9% nationally, for cases diagnosed from 2016–2022. The figures are not risk-adjusted.
Learn how Sylvester’s Brain Tumor Institute is advancing personalized care: spr.ly/6012BHnANK
Dr. Estela Rodriguez retweeted
As @RajaFlores points out, oncology has a language problem, including how to define "early stage". cancerletter.com/perspective…
For patients & families "early stage" sounds reassuring:
✅ Caught early
✅ Treated
✅ Cured
But in #lungcancer, even stages I and II have a significant risk of recurrence. I know firsthand how devastating it is to be diagnosed with Stage Ia, believe I'm cured, experience recurrence, and learn I have advanced-stage disease.
Of course staging matters. But stage is not a prognosis, and patients aren't statistics. For patients and families, the real question is, "What does that stage mean for me, my family, my life?"
Because understanding your stage is not the same as understanding your cancer.
#LCSM #WordsMatter #staging @TheCancerLetter @DrewMoghanaki
Dr. Estela Rodriguez retweeted
Getting ready for @myesmo #ESMO26?
Here are the top ten #LCSM presentations by @oncoalert
@SclcSMASHERS @FDA @LUNGevity @lungoncdoc @StephenVLiu @HHorinouchi @g_mountzios @sands_jacob @LauraAlderMD @oncodaily @OncoAlert @Latinamd @LuisPaz_Ares @RManochakian @LuisRaezMD @triparnasen @LaurenByersMD @LungCancerEu @alissajcooper @BZhangMD @NaglaAKarimMD @Annechiangmd @IASLC @NCCN @ASCO #ESMO26 @larvol @tribeMDUS @sylvestercancer @oncbrothers @chinmay @Jani_Chinmay @colazagasti @openmedicineHQ @myesmo @openmedkate @openmedben @chadinabhan @YoungLungCancer @OncodailyLung @ClinicalLung #LCSM @LungPolicy @dan_morgxen
🚨 #ESMO26 Lung Cancer: Top Ten by @OncoAlert 🫁
The abstracts our faculty picked as must-know from Madrid 👇
1️⃣ DeLLphi-305 (LBA3): tarlatamab + durvalumab, 1L maintenance in ES-SCLC
2️⃣ Krascendo 1 (LBA5): divarasib vs sotorasib/adagrasib in KRAS G12C NSCLC
3️⃣ SAFFRON (LBA6): osimertinib + savolitinib in EGFRm MET+ NSCLC post-osimertinib
4️⃣ OptiTROP-Lung04 (LBA67): final OS, sac-TMT vs chemo after EGFR-TKI
5️⃣ OptiTROP-Lung06 (LBA66): sac-TMT + pembro, 1L PD-L1-negative non-squamous NSCLC
6️⃣ PERSEE (2614O): pembro ± chemo, 1L PD-L1 ≥50%
7️⃣ SANOVO (LBA69): savolitinib + osimertinib, 1L EGFRm MET-overexpressed NSCLC
8️⃣ IFCT-2103 DIAL (2618RO): continue pembro vs observation at 6 months
9️⃣ PANKU-Lung01 (LBA71): iza-bren after third-generation EGFR TKI
🔟 SARON (2613O): consolidation radiotherapy in oligometastatic NSCLC
#lcsm #OncoAlert #MedTwitter
Pinging our OncoAlert Lung Cancer Faculty
@christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @jillfeldman4, @UOzkerim, @DrMirallas, @MartinReck2 , @bmassutis @UmbertoMalapel1 , @CharuAggarwalMD
@peters_solange, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @VanitaNoronha, @ChristianRolfo @Tony_Calles @s_couraud @marinagarassino @g_mountzios @BairdAM @barlesi @JFreemanDaily @Piuchagarrido @LeciaSequist @bensolomon1 @VanitaNoronha +@alexdrilon @JordiRemon @caliraf @JulienMazieres @TerriConneran
5️⃣ days to go for @flasco_voiceofoncology Women’s Cancer Care Conference -
a full day of panels dedicated to women’s health across the cancer continuum from diagnosis to survivorship
📆Saturday, October 24, 2026, 8:20 am to 4PM
📍Hotel Colonnade Coral Gables
📖 5.5 CME
FREE for @FLASCO_ORG members
@sylvestercancer
Register at flasco.org/events/cos-flasco…
👏👏Great to see two former members of the @SylvesterCancer Thoracic Working Group listed as presenters at the Fall @eaonc Young Investigator Symposium- @FahminB_MDPhD now @DukeCancer and @Jani_Chinmay now faculty @SylvesterCancer #proudmentor
Meet the 2026 ECOG-ACRIN Young Investigator Symposium presenters, who will share innovative #CancerResearch tomorrow in Philadelphia: bit.ly/YIS26
@JithmaA @FahminB_MDPhD @FedGhali @Jani_Chinmay @CathyHandy @ShachiMittal2 @fangdisun @VarshaS53228024 & Allison Matous
